These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8630238)

  • 21. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU; Weigel NL
    J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility.
    Ross RK; Pike MC; Coetzee GA; Reichardt JK; Yu MC; Feigelson H; Stanczyk FZ; Kolonel LN; Henderson BE
    Cancer Res; 1998 Oct; 58(20):4497-504. PubMed ID: 9788589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
    Bergerat JP; Céraline J
    Hum Mutat; 2009 Feb; 30(2):145-57. PubMed ID: 18800375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current situation of researches on the molecule mechanism of hormone refractory prostate cancer].
    Yang NQ; Wang YX
    Zhonghua Nan Ke Xue; 2006 Jun; 12(6):551-4. PubMed ID: 16833202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In situ androgen producing enzymes in human prostate cancer.
    Nakamura Y; Suzuki T; Nakabayashi M; Endoh M; Sakamoto K; Mikami Y; Moriya T; Ito A; Takahashi S; Yamada S; Arai Y; Sasano H
    Endocr Relat Cancer; 2005 Mar; 12(1):101-7. PubMed ID: 15788642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The androgen receptor gene mutations database (ARDB): 2004 update.
    Gottlieb B; Beitel LK; Wu JH; Trifiro M
    Hum Mutat; 2004 Jun; 23(6):527-33. PubMed ID: 15146455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
    Luo J; Dunn TA; Ewing CM; Walsh PC; Isaacs WB
    Prostate; 2003 Oct; 57(2):134-9. PubMed ID: 12949937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R726L androgen receptor mutation is uncommon in prostate cancer families in the united states.
    Gruber SB; Chen H; Tomsho LP; Lee N; Perrone EE; Cooney KA
    Prostate; 2003 Mar; 54(4):306-9. PubMed ID: 12539229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease.
    Duff J; Davies P; Watt K; McEwan IJ
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1098-102. PubMed ID: 17073759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
    Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
    Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular regulation of androgen action in prostate cancer.
    Dehm SM; Tindall DJ
    J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.
    Agoulnik IU; Vaid A; Bingman WE; Erdeme H; Frolov A; Smith CL; Ayala G; Ittmann MM; Weigel NL
    Cancer Res; 2005 Sep; 65(17):7959-67. PubMed ID: 16140968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
    Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
    J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement.
    Shibata A; Stamey TA; McNeal JE; Cheng I; Peehl DM
    J Urol; 2001 Oct; 166(4):1560-4. PubMed ID: 11547131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostatic growth: new insights into hormonal regulation.
    McConnell JD
    Br J Urol; 1995 Jul; 76 Suppl 1():5-10. PubMed ID: 7544215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.